Opportunities arise for companies when copycat drugs are just as good as the original. The Canadian company XPhyto has taken a big step toward market readiness in the fight against Parkinson's disease. Over the next five minutes, we briefly explain what is important now and how great the opportunities are. We also show how XPhyto is helping to counter the opioid wave in the USA and what imagination lies in the little-noticed business field of psychedelics.Den vollständigen Artikel lesen ...
© 2022 researchanalyst.com (EN)